Earnings ·
Metagenomi Therapeutics reported second quarter 2026 financial results and business updates
MGXMetagenomi Therapeutics, Inc.
Metagenomi Therapeutics reported second quarter 2026 financial results and business updates. The company held $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with a runway supporting operations through the fourth quarter of 2027. Research and development expenses were $22.5 million for the quarter, while general and administrative expenses decreased to $6.0 million from $7.0 million in the prior year period. The company reported a net loss of $27.48 million, or $0.73 per share. Metagenomi remains on track to submit an investigational new drug application for its MGX-001 hemophilia A program in the fourth quarter of 2026 and expects IND-enabling studies to be complete by the end of the third quarter. The company operates as an in vivo genome editing firm developing curative genetic medicines.